Merus MRUS 深 沪
等待开盘 02-02 09:30:00 美东时间
90.00
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 90.00
- 总市值 68.21亿
- 52周最高 97.14
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 33.19
- 委 比 0.00%
- 总股本 7578.44万
- 历史最高 97.14
- 量 比 0
- 振 幅 0.00%
- 历史最低 7.255
- 每 手 1
- 风险率 21.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Merus Completes Genmab Acquisition and Delists From Nasdaq
Merus ( ($MRUS) ) has provided an update. On September 29, 2025, Merus N.V. ent...
2025-12-30 22:17
Genmab ends development of late-stage oncology asset acasunlimab
Genmab (GMAB) has decided to discontinue development of acasunlimab, which was in phase 3 for non-small cell lung cancer, to focus on other assets in its pipeline as well as its marketed product, Epki...
2025-12-29 23:07
健玛生物终止一款在研抗癌疗法研发
丹麦药企健玛生物（Genmab）周一宣布，将终止一款已进入后期临床试验的在研抗体抗癌疗法的研发工作。 2024 年，百欧恩泰（BioNTech）决定不再...
2025-12-29 22:11
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors ...
2025-12-17 02:17
Merus Acquired by Genmab, Leadership Changes Announced
An announcement from Merus ( ($MRUS) ) is now available. On December 11, 2025, ...
2025-12-12 21:18
Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer
Genmab's Epkinly receives traditional FDA approval for relapsed or refractory follicular lymphoma in combination and monotherapy. Clinical trial data show superior results.
2025-11-19 01:58
Merus N.V. Shareholders to Vote on Genmab Acquisition Offer
New activity is brewing for Merus ( ($MRUS) ). The company has submitted a Form...
2025-11-12 21:40
Merus Announces Interim Clinical Data From Ongoing Phase 2 Trial Of Bispecific Antibody Petosemtamab In Metastatic Colorectal Cancer In Combination With FOLFOX/FOLFIRI
– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed)– 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct.
2025-10-24 22:04
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
Merus N.V. announced interim results from a phase 2 trial of petosemtamab in metastatic colorectal cancer (mCRC). In 1L left-sided mCRC, 100% response rate was observed (n=8). In 2L mCRC, a 62% response rate was noted (n=13). Petosemtamab showed promising efficacy and a consistent safety profile across treatment lines, with no new safety signals identified. These findings highlight its potential as a transformative treatment for mCRC patients.
2025-10-24 14:00
Why Is Genmab Stock Trading Lower On Monday?
Genmab reported a 50% response rate and durable results for Rina-S in advanced endometrial cancer, with manageable side effects and no major toxicities.
2025-10-20 23:57
